Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06860594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06860594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
July 30, 2025
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, idh-mutant, grade 2, recurrent adult diffuse hemispheric glioma, h3 g34-mutant, recurrent adult diffuse midline glioma, h3 k27-mutant, recurrent astrocytoma, idh-mutant, recurrent astrocytoma, idh-mutant, grade 3, recurrent astrocytoma, idh-mutant, grade 4, recurrent glioblastoma, idh-wildtype